LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial
Bas Groot Koerkamp, Quisette P. Janssen, Jacob L. van Dam, Bert A. Bonsing, H Bos, Koop Bosscha, Brigitte C.M. Haberkorn, Ignace H. J. T. de Hingh, Tom M. Karsten, M. B. van der Kolk, Mike S.L. Liem, O. J. L. Loosveld, G.A. Patijn, H.C.M. van Santvoort, Judith de Vos‐Geelen, Bronno van der Holt, Marta Homs, Geertjan van Tienhoven, Marc G. Besselink, Hanneke Wilmink
Topics & Concepts
MedicineFOLFIRINOXGemcitabineClinical endpointHazard ratioNeoadjuvant therapyRandomizationPancreatic cancerSurgeryChemoradiotherapyInternal medicineRadiation therapyOncologyChemotherapyRandomized controlled trialCancerConfidence intervalIrinotecanColorectal cancerBreast cancerPancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsEsophageal Cancer Research and Treatment